NCT00850577 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated
Clinical Trials
6 trialsNCT00851045 2015-10-12
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT01146171 2012-02-07
Japanese Phase 1 Study of BMS-844203 (CT322)
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00562419 2010-10-27
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 2 Unknown
NCT00768911 2010-10-27
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 1 Unknown
NCT00374179 2009-02-24
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 1 Completed